N/A Completed N=24 Randomized Single-blind Basic Science

Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults

Oxygen Consumption

Source: ClinicalTrials.gov NCT02802111 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2020

Primary outcomePrimary: Oxygen Consumption — .28; .27 mls/kg/min

Summary

Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity. The investigators sought to examine the changes in oxygen consumption (V'O2) and Heart Rate (HR) following administration of albuterol and

Outcome Measures

Outcome	Result	p-value
PRIMARY Oxygen Consumption	.28; .27	—
SECONDARY Heart Rate	91; 93	—

Eligibility Criteria

Inclusion Criteria

Healthy volunteers between the ages of 18 and 60 years

Exclusion Criteria

Coronary artery disease, history of intolerance to beta agonists

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02802111). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.